A high-throughput screen for candidate agents that may reverse gamma-globin silen
对可能逆转伽马珠蛋白沉默的候选药物进行高通量筛选
基本信息
- 批准号:7532720
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:Acute Erythroblastic LeukemiaAdultAffectAliquotBiological AssayBiological ModelsCaringCell Culture TechniquesCell LineCellsCessation of lifeChemicalsChildhoodChromatinClone CellsCountryCulture MediaDeveloped CountriesDeveloping CountriesDiseaseEpigenetic ProcessErythrocytesErythroid CellsEukaryotaFailureFluorescence-Activated Cell SortingGenesGenomeGenomicsGlobinGoalsHealthcare SystemsHemoglobinopathiesHereditary DiseaseHistone Deacetylase InhibitorIndividualLeadLifeMammalian CellMedicalMethodologyMethodsMolecularMorbidity - disease rateMusNaturePharmaceutical PreparationsPilot ProjectsProceduresProductionPublic HealthPublishingReporterReporter GenesSafetyScreening procedureSickle Cell AnemiaSiteSolutionsSorting - Cell MovementStagingSystemTestingThalassemiaTherapeutic AgentsTransgenesbasecell typeearly childhoodeffective therapyerythroid differentiationexperiencefetal globingamma Globinhigh throughput screeningmortalitynovelpreventpublic health relevanceresponsescale upsmall molecule librariestooltransgene expression
项目摘要
DESCRIPTION (provided by applicant): The ?-hemoglobinopathies sickle cell disease and ?-thalassemia are among the most common, and most devastating, genetic diseases worldwide. In countries with developed health care systems, care for affected individuals is extremely expensive; in developing countries most affected individuals receive substandard or no care, and death in childhood is common. It has long been known that enhanced production of (fetal) ?-globin expression can ameliorate or prevent both diseases, as ?-globin substitutes for the defective ?-globin. A safe and effective drug that will accomplish this has long been sought, but it has been difficult to devise effective high-throughput assays. Here we propose to develop an assay that may produce candidate compounds that have activity in reversing ?-globin silencing in adult-stage red blood cells. This is a cell-based assay that relies on a new application of tried methodology developed by the PI; it is capable of screening many thousands of compounds. These compounds may serve as leads to new classes of active molecules, and can be tested for specific activity in experimental systems that reproduce globin switching. This is a pilot study intended to develop and explore the assay, but the initial testing has revealed that it is capable of identifying compounds with previously undescribed epigenetic activity. This study could thus open a new avenue of approach to a stubborn problem, the solution to which could affect millions of lives worldwide. PUBLIC HEALTH RELEVANCE: Sickle cell disease and _-thalassemia are devastating genetic diseases that are extremely common worldwide and increasingly common in the USA; current medical treatment for them is inadequate and expensive. A cheap and effective drug that could reactivate fetal globin expression would have a major impact on worldwide morbidity and mortality from these diseases, and ease a considerable burden on the health care systems of many developing countries. This proposal presents a new method of searching for chemical compounds that might provide such a cheap and effective treatment; thus it has a potential for a broad impact on public health.
描述(由申请人提供):血红蛋白病镰状细胞病和?地中海贫血是全世界最常见和最具破坏性的遗传疾病之一。在卫生保健系统发达的国家,对受影响者的护理极其昂贵;在发展中国家,大多数受影响者得到的护理低于标准或得不到护理,儿童死亡很常见。人们早就知道,(胎儿)?珠蛋白的表达可以改善或预防这两种疾病,如?珠蛋白替代品的缺陷?珠蛋白长期以来,人们一直在寻找一种安全有效的药物来实现这一目标,但很难设计出有效的高通量检测方法。在这里,我们建议开发一种检测方法,可以产生具有逆转活性的候选化合物。成熟期红细胞中的珠蛋白沉默。这是一种基于细胞的检测方法,依赖于PI开发的尝试方法的新应用;它能够筛选数千种化合物。这些化合物可以作为新的活性分子类别的线索,并且可以在再现珠蛋白转换的实验系统中测试特定活性。这是一项旨在开发和探索该检测方法的试点研究,但初步测试表明,它能够识别具有先前未描述的表观遗传活性的化合物。因此,这项研究可以为解决一个顽固问题开辟一条新的途径,解决这个问题可能会影响到全世界数百万人的生活。公共卫生关系:镰状细胞病和地中海贫血是毁灭性的遗传性疾病,在世界范围内非常常见,在美国也越来越常见;目前对它们的医学治疗是不充分和昂贵的。一种能够重新激活胎儿珠蛋白表达的廉价而有效的药物将对这些疾病的全球发病率和死亡率产生重大影响,并减轻许多发展中国家卫生保健系统的相当大的负担。该提案提出了一种寻找可能提供这种廉价有效治疗的化合物的新方法;因此,它有可能对公共卫生产生广泛影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Ian Kingston Martin其他文献
David Ian Kingston Martin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Ian Kingston Martin', 18)}}的其他基金
A high-throughput screen for candidate agents that may reverse gamma-globin silen
高通量筛选可能逆转伽马珠蛋白沉默的候选药物
- 批准号:
7851313 - 财政年份:2009
- 资助金额:
$ 24万 - 项目类别:
Epigenetic Suppression of the Obese Yellow Phenotype
肥胖黄色表型的表观遗传抑制
- 批准号:
7102832 - 财政年份:2005
- 资助金额:
$ 24万 - 项目类别:
Germline epimutation of hMLH1 as a factor in HNPCC
hMLH1 种系表突变作为 HNPCC 的一个因素
- 批准号:
7076832 - 财政年份:2005
- 资助金额:
$ 24万 - 项目类别:
Germline epimutation of hMLH1 as a factor in HNPCC
hMLH1 种系表突变作为 HNPCC 的一个因素
- 批准号:
6856870 - 财政年份:2005
- 资助金额:
$ 24万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 24万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




